ArticleAnti-cancer drugs2014
Life-threatening dermatologic adverse events in oncology.
Article in Anti-cancer drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020.Frontiers in medicine · 2022Pooled it
- Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review.Drugs in R&D · 2020Pooled it
- Dermatological adverse events with taxane chemotherapy.European journal of dermatology : EJD · 2016Pooled it
- Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.The oncologist · 2022Trial
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies.Biomedicines · 2025Review
- Incidence, management, and outcomes of procarbazine-associated hypersensitivity reactions in patients receiving PCV for lower-grade gliomas.Neuro-oncology practice · 2025Article
- Anti-Cancer Drug-Induced Lyell's Syndrome: A Series of Two Patients.Current oncology (Toronto, Ont.) · 2024Article
- Severe cutaneous adverse reactions.Nature reviews. Disease primers · 2024Review
- Article
- Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults.Neuro-oncology · 2023Article
- Article
- Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.Journal of inflammation research · 2023Article
- Mitigating acute chemotherapy-associated adverse events in patients with cancer.Nature reviews. Clinical oncology · 2022Review
- Culprit Medications and Risk Factors Associated with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case-Control Study.American journal of clinical dermatology · 2022Article
- Daunorubicin induced Stevens-Johnson syndrome: A case report.Clinical case reports · 2021Article
- Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).Oncology reports · 2021Review
- Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Article
- Ribociclib-Related Stevens-Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review.Journal of breast cancer · 2019Article
- Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data.The oncologist · 2019Article
- Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System.Cancer medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
The incidences of life-threatening toxicities such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are inconsistently reported. The potential association of anticancer agents with SJS or TEN has not been systematically investigated. We searched the literature (Ovid: 1950 to June 2013 and PubMed: 1948 to June 2013) using terms for SJS/TEN and anticancer therapies. Primary case reports, case series, and clinical trials were included. In addition, MedWatch, the Food and Drug Administration Adverse Event Reporting System (FAERS), was searched (1968 to August 2012) for SJS/TEN reports associated with anticancer therapies. Proportional reporting ratios (PRR>2, N>3), empirical Bayes geometric mean (EBGM>2, N>3), and lower 95% confidence interval (EBGM0.05>2) were used as thresholds to constitute a signal of association between SJS/TEN and anticancer drugs. There were 46 SJS and 37 TEN cases associated with 18 and 22 anticancer drugs in the literature, respectively. Among cases in the FAERS, significant signals were associated with SJS for bendamustine and with TEN for bendamustine, busulfan, chlorambucil, fludarabine, lomustine, and procarbazine. Several drugs reported in the published literature to be associated with SJS/TEN were not found to have significant signals in FAERS. Proactive pharmacovigilance to detect and define safety signals serves to aid oncology practitioners in the recognition of possible, yet uncommon, serious, and/or life-threatening skin reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.